The results from the full cohort analysis of the REVERSE-AD study provide compelling evidence for idarucizumab’s ability to immediately, completely and sustainably reverse the anticoagulant effect of dabigatran.

This video summarizes the key results of the RE-VERSE AD study and shows the importance of specific reversibility in the context of anticoagulation